Patents by Inventor John M. Lambert

John M. Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200055177
    Abstract: A powered fastener driver for driving fasteners into a workpiece includes a driver unit and a handle unit selectively and removably attachable to the driver unit. The driver unit includes a housing, a motor, and a first coupler. The handle unit includes a battery receptacle for receiving a battery pack, a trigger, and a second coupler. The first and second couplers selectively engage one another to mechanically and electrically connect the driver unit to the handle unit.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 20, 2020
    Inventors: John S. Scott, Gareth Mueckl, Caroline Hope, Isabel M. Lloyd, Matthew Post, Adam N. Carter, Jonathan L. Lambert, Logan M. Hietpas, Matthew N. Thurin, Paul Fry, Julia L. Savich
  • Patent number: 10313010
    Abstract: Systems, methods, and apparatus for laser communications in super-geosynchronous Earth orbit are disclosed. In one or more embodiments, the disclosed method involves transmitting, by at least one laser on at least one first satellite, at least one first transmit signal. The method further involves receiving, by at least one detector on at least one first satellite, at least one first receive signal. In one or more embodiments, at least one first satellite is in super-geosynchronous Earth orbit (S-GEO). In at least one embodiment, at least one first transmit signal and at least one first receive signal are laser signals and have a field of regard covering one hemisphere of the Earth.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: June 4, 2019
    Assignee: The Boeing Company
    Inventors: Matthew M. Everett, John P. Leuer, David A. Whelan, Stephen G. Lambert
  • Publication number: 20190038762
    Abstract: This invention relates to antibody-drug conjugates capable of delivering cytotoxic compounds to cancers expressing the guanylyl cyclase C (GCC) transmembrane cell surface receptor.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., IMMUNOGEN, INC.
    Inventors: Ole Petter VEIBY, Ravi V. J. CHARI, John M. LAMBERT, Katharine C. LAI, Robert W. HERBST, Scott A. HILDERBRAND
  • Patent number: 8388960
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: March 5, 2013
    Assignee: Immunogen Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson, Wayne C. Widdison
  • Patent number: 8137669
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: March 20, 2012
    Assignee: Immunogen, Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V. J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson
  • Publication number: 20110319612
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Application
    Filed: September 9, 2011
    Publication date: December 29, 2011
    Applicant: IMMUNOGEN INC.
    Inventors: Viktor S. GOLDMAKHER, Robert J. LUTZ, Ravi V.J. CHARI, Yelena V. KOVTUN, John M. LAMBERT, Rita STEEVES, Hans K. ERICKSON
  • Publication number: 20090076263
    Abstract: Methods of killing or inhibiting tumors comprising of heterogeneous or mixed cell populations is described. The killing or inhibition of tumors is achieved by selectively targeting a unique ligand suspected of being expressed on a particular cell population to also kill a cell population lacking the unique ligand. These conjugates have therapeutic use as they are delivered to a specific cell population to kill these cells and the cytotoxic drug is released to kill non-targeted cells, thereby eliminating the tumor.
    Type: Application
    Filed: August 5, 2008
    Publication date: March 19, 2009
    Applicant: ImmunoGen Inc.
    Inventors: Viktor S. Goldmakher, Robert J. Lutz, Ravi V.J. Chari, Yelena V. Kovtun, John M. Lambert, Rita Steeves, Hans K. Erickson
  • Patent number: 5416064
    Abstract: A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier, diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.
    Type: Grant
    Filed: December 7, 1992
    Date of Patent: May 16, 1995
    Assignee: ImmunoGen, Inc.
    Inventors: Ravi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. Blattler
  • Patent number: 5395924
    Abstract: An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to the lectin to thereby block one or more of the binding sites of the lectin. A blocked lectin is described comprising one or more affinity ligands covalently linked by means of a reactive group present on each of the ligands to a lectin such that one or more binding sites of the lectin is blocked. A cell-binding agent-blocked lectin conjugate is described comprising the above-described blocked lectin and a cell-binding agent covalently linked to: (a) one of the covalently linked affinity ligands; or (b) the lectin. A method of preparing the cell-binding agent-blocked lectin conjugate is described. An affinity support capable of binding to a lectin to form a blocked lectin is described comprising an activated affinity ligand covalently linked to a solid support.
    Type: Grant
    Filed: February 19, 1993
    Date of Patent: March 7, 1995
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Victor S. Goldmacher, Ravi V. J. Chari, Charles F. Scott, Jr., Linda J. Kostuba, Simon E. Moroney, Albert R. Collison
  • Patent number: 5239062
    Abstract: An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to the lectin to thereby block one or more of the binding sites of the lectin. A blocked lectin is described comprising one or more affinity ligands covalently linked by means of a reactive group present on each of the ligands to a lectin such that one or more binding sites of the lectin is blocked. A cell-binding agent-blocked lectin conjugate is described comprising the above-described blocked lectin and a cell-binding agent covalently linked to: (a) one of the covalently linked affinity ligands; or (b) the lectin. A method of preparing a blocked lectin is described. A method of preparing the cell-binding agent-blocked lectin conjugate is described. An affinity support capable of binding to a lectin to form a blocked lectin is described comprising an activated affinity ligand covalently linked to a solid support.
    Type: Grant
    Filed: July 31, 1990
    Date of Patent: August 24, 1993
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Victor S. Goldmacher, Ravi V. J. Chari, Charles F. Scott, Jr., Linda J. Kostuba, Simon E. Moroney, Albert R. Collinson
  • Patent number: 5208020
    Abstract: A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.
    Type: Grant
    Filed: July 13, 1992
    Date of Patent: May 4, 1993
    Assignee: ImmunoGen Inc.
    Inventors: Ravi J. Chari, Victor S. Goldmacher, John M. Lambert, Walter A. Blattler
  • Patent number: 4888415
    Abstract: Immunotoxins having improved toxic activity have the composition ##STR1## wherein Toxin-NH is a ribosome-inactivating protein containing no accessible sulfhydryl groups, n is an integer from 1 to 5, m is an integer from 1 to 5, and NH-Antibody is a monoclonal antibody specific to eucaryotic cells or antigens associated therewith. The immunotoxins are made by reacting the Toxin-NH with an iminothiolester salt to form a first conjugate, reacting the NH-Antibody with N-succinimidyl-3-(2-pyridyldithio) propionate to form a second conjugate, and reacting the two conjugates to form the immunotoxin.
    Type: Grant
    Filed: March 7, 1988
    Date of Patent: December 19, 1989
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: John M. Lambert, Walter A. Blattler, Peter D. Senter
  • Patent number: 4764368
    Abstract: Heterobifunctional reagents that are cleavable under mildly acidic conditions are disclosed. The reagents include an acid cleavable cyclohexene-1,2,-dicarboxylic acid monoamide group. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structures. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: September 17, 1986
    Date of Patent: August 16, 1988
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert
  • Patent number: 4625014
    Abstract: A photo-cleavable compound for delivery and release of a biologically active substance to selected target cells; the compound includes a binding partner for a specific cell-surface receptor of those target cells, the biologically active substance to be delivered, and a photo-cleavable bridge between the binding partner and the biologically active substance. When the compound is exposed to a heterogeneous population of target and non-target cells, it binds selectively to the receptors on the surface of the target cells. Exposing the compound to light of selected wave length cleaves it, yielding the active substance.
    Type: Grant
    Filed: July 10, 1984
    Date of Patent: November 25, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Peter D. Senter, John M. Lambert, Walter A. Blattler
  • Patent number: 4618492
    Abstract: Amino-sulfhydryl cross-linking reagents that are cleavable under mildly acidic conditions are disclosed. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structure. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: May 13, 1985
    Date of Patent: October 21, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Peter D. Senter
  • Patent number: 4569789
    Abstract: Amino-sulfhydryl cross-linking reagents that are cleavable under mildly acidic conditions are disclosed. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structures. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: April 26, 1985
    Date of Patent: February 11, 1986
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Peter D. Senter
  • Patent number: 4542225
    Abstract: Amino-sulfhydryl cross-linking reagents that are cleavable under mildly acidic conditions are disclosed. Also disclosed are methods of making the cross-linkers, as well as methods of using the cross-linkers, e.g., to deliver a biologically active substance across the membranes of selected cells in a heterogeneous cell population; once inside the cell the active substance is released, intact, by the transient, mild acidity of certain cell structures. Finally, a method of characterizing complex multi-chain protein structures is disclosed.
    Type: Grant
    Filed: August 29, 1984
    Date of Patent: September 17, 1985
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Walter A. Blattler, John M. Lambert, Peter D. Senter